Inflammatory Bowel Disease: From Bench to BedsideStephan R. Targan, Fergus Shanahan, Loren C. Karp Inflammatory Bowel Disease: From Bench to Bedside is a detailed and comprehensive story of the local and systemic pathophysiology of intestinal inflammation including management strategies. Research advances and current concepts of etiopathogenesis in the context of what is already known of the clinicopathologic features of these disorders are explored. This volume blends recent advances in the basic and clinical sciences as they relate to inflammatory bowel disease and emphasizes the effectiveness of a team approach of basic scientists and clinician investigators in this field. |
Contents
| 5 | |
| 19 | |
Genetics of inflammatory bowel disease | 64 |
a state of controlled inflammation | 101 |
The lymphocyteepithelialbacterial interface | 121 |
The mucosal inflammatory response Cytokines and chemokines | 147 |
Role of the microcirculation in chronic gut inflammation | 177 |
Antibodies in the exploration of inflammatory bowel disease pathogenesis | 210 |
optimizing current medical therapy | 495 |
Multisite therapeutic modalities for inflammatory bowel diseases mechanisms of action | 522 |
Targeted therapies for inflammatory bowel disease | 553 |
Role of antibiotics and probiotics in the management of inflammatory | 572 |
Nutrition in inflammatory bowel disease | 587 |
Medical management of ulcerative colitis | 605 |
Surgical management of ulcerative colitis | 630 |
Medical therapy for Crohns disease | 659 |
Systemic consequences of intestinal inflammation | 235 |
Understanding symptoms and signs in inflammatory bowel disease | 253 |
Clinical course and complications of ulcerative colitis and ulcerative proctitis | 268 |
Clinical features and complications of Crohns disease | 291 |
Mechanisms of systemic inflammation associated with intestinal injury | 305 |
a critical appraisal in diagnosis and management | 337 |
when where and what to | 356 |
Radiologic radiographic and imaging features of ulcerative colitis and Crohns disease | 371 |
New diagnostic approaches in inflammatory bowel disease | 409 |
Differential diagnosis of colitis | 430 |
Disease management in chronic medical conditions | 457 |
Pharmacoeconomics and inflammatory bowel disease | 471 |
Postoperative prevention of recurrence of Crohns disease | 697 |
The molecular pathology of inflammatory bowel diseaseassociated neoplasia and preneoplasia | 710 |
Hepatobiliary disorders | 731 |
Articular and ocular complications of inflammatory bowel disease | 746 |
Fertility and pregnancy in inflammatory bowel disease | 763 |
collagenous and lymphocytic colitis | 791 |
Diversion colitis | 811 |
Infectious colitis | 845 |
Human immunodeficiency virus and inflammatory bowel disease | 863 |
Bench to bedside and back to bench | 885 |
Other editions - View all
Inflammatory Bowel Disease: From Bench to Bedside Stephan R. Targan,Fergus Shanahan,Loren C. Karp Limited preview - 2005 |
Inflammatory Bowel Disease: From Bench to Bedside Stephan R. Targan,Fergus Shanahan,Loren C. Karp No preview available - 2003 |
Common terms and phrases
activity antibodies antigens apoptosis arthritis ASCA associated bacterial binding biopsies CD4+ T cells chemokines chronic Clin Invest clinical colectomy colon Crohn's disease crypt cytokines diagnosis diarrhea distal drug dysplasia effects endoscopic endothelial cells epithelial cells epithelium expression fistulas flora function Gastroenterology gastrointestinal gene genetic glucocorticoid growth factor HRQL human IBD patients IFN-y ileal immune response Immunol increased induced infection inflammation inflammatory bowel disease infliximab inhibition interactions interleukin intestinal epithelial cells intestinal inflammation involved lamina propria lesions leukocyte levels lymphocytes macrophages markers mechanisms mediated methotrexate mice mucosal neutrophil normal oral pANCA pathogenesis pathogenic patients with IBD peptide pouchitis primary sclerosing cholangitis production proinflammatory protein rats reactive receptor rectal regulation role Scand J Gastroenterol serum small bowel small intestine specific studies sulfasalazine susceptibility Targan TGF-ẞ therapeutic therapy tion tissue transgenic treatment UC patients ulcerative colitis